Reply to letter to the editor "antibody responses to second doses of COVID-19 vaccination in lung cancer patients: Comment"

Respir Investig. 2023 May;61(3):347-348. doi: 10.1016/j.resinv.2023.02.004. Epub 2023 Mar 7.

Authors

Daisuke Narita¹, Risa Ebina-Shibuya²

Affiliations

¹ Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aobaku, Sendai, Miyagi, 980-8574, Japan.
² Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aobaku, Sendai, Miyagi, 980-8574, Japan. Electronic address: r.shibuya@rm.med.tohoku.ac.jp.

No abstract available

Keywords: COVID-19; Lung cancer; SARS-CoV-2; Vaccination.

Publication types

Letter

MeSH terms

Antibody Formation
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Lung Neoplasms*
Vaccination

Substances

COVID-19 Vaccines